Human Laboratory Study of Apremilast for Alcohol Use Disorder
Status:
NOT_YET_RECRUITING
Trial end date:
2027-07-31
Target enrollment:
Participant gender:
Summary
Primary: The primary objective of this study is to compare the efficacy of two different maintenance doses of apremilast (tablets) in reducing alcohol craving among subjects with moderate to severe alcohol use disorder (AUD) after two weeks of daily dosing.
Secondary: Secondary objectives include evaluation of two different maintenance doses of apremilast compared with matched placebo on other measures of self-reported alcohol consumption, alcohol craving, alcohol-related negative consequences, AUD symptoms, pain, sleep disturbances, depression, anxiety, quality of life, cigarette smoking, other nicotine use, cannabis use, retention in the study, and safety.
Phase:
PHASE2
Details
Lead Sponsor:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)